Company: RCUS
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001724521-25-000052
Chunk: 48

Company: Arcus Biosciences, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 48
---
 AB598, through dose escalation and potentially into expansion cohorts; and

• securing funding to support a significant cash runway that extends through mid-2027.

We do not disclose the specific portions or weighting of these goals, because they include highly sensitive and competitive data, and therefore, we believe that such disclosure would result in competitive harm to us.

The Compensation Committee does not use a formula to calculate any individual’s performance. Rather, it evaluates the totality of the company’s achievements relative to its corporate goals, overall progress and performance and contribution towards the creation of long-term stockholder value, and each individual's contributions. Achievements considered by the Compensation Committee include the “2024 Business Highlights” discussed above and the 2024 bonuses approved by the Compensation Committee for each named executive officer are set forth below:

| Name and Title                                               |     | 2024 Bonus Target 
 (%)               |     | 2024 Bonus Target 
 ($)               |         |     | Bonus Payout for 2024 Performance 
 ($)                               |         |
| Terry Rosen, Ph.D., Chief Executive Officer                  |     | 85%               |     |                   | 616,250 |     |                                   | 615,000 |
| Robert C. Goeltz, II, Chief Financial Officer                |     | 45%               |     |                   | 229,500 |     |                                   | 230,000 |
| Juan Carlos Jaen, Ph.D., President                           |     | 50%               |     |                   | 312,500 |     |                                   | 315,000 |
| Jennifer Jarrett, Chief Operating Officer                    |     | 50%               |     |                   | 312,500 |     |                                   | 315,000 |
| Dimitry Nuyten, M.D., Ph.D., former Chief Medical Officer(1) |     | 45%               |     |                   | 263,250 |     |                                   | 250,000 |

(1) Dr. Nuyten terminated employment with us on January 31, 2025. The 2024 bonus payout reported here was made pursuant to our Severance Benefits Plan. See Severance and Change in Control Benefits below for more information.

The Compensation Committee considered our 2024 achievements, particularly the acceleration of enrollment for STAR-221 and the overall progress of our clinical development pipeline, which the Committee considered critical to the company’s success. In recognition of Dr. Rosen’s leadership of the company, the Compensation Committee awarded him